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Abstract
Background: The pathogenesis of cardiovascular (CV) mortality, whose rate is increased in type 2 diabetes, is
poorly understood.
While high serum adiponectin is associated with increased CV mortality in the general population, no data are
available in type 2 diabetes.
We here investigated whether this counterintuitive association was observable also in diabetic patients and
whether it was sex-specific.
Methods: Three prospective cohorts were analyzed: 1) Gargano Heart Study (GHS; 359 patients, 58 events/1,934
person-years; py); 2) Health Professional Follow-up Study (HPFS; 833 men, 146 events/10,024 py); 3) Nurses’ Health
Study (NHS; 902 women, 144 events/15,074 py).
Results: In GHS serum adiponectin predicted CV mortality in men (hazard ratio, HR, and 95% CI per standard
deviation, SD, increment= 1.54, 1.19-2.01), but not women (HR= 0.98, 0.48-2.01).
Circulating adiponectin predicted CV mortality in men from HPFS (HR =1.44, 1.21-1.72), but not in women from
NHS (HR =1.08, 0.86-1.35), used as replication samples. In a pooled analysis, HRs were 1.47 (1.27-1.70) in 1,075 men
and 1.07 (0.86-1.33) in 1,019 women (p for HRs heterogeneity across sexes = 0.018).
Conclusions: This is the first report showing that high circulating adiponectin predicts increased CV mortality in
men, but not in women with type 2 diabetes. Further studies are necessary to unravel the mechanisms through
which adiponectin influences CV mortality in a sex-specific manner.
Keywords: Adipokines, Prospective studies, Paradoxical effect, Sex-linked genes
The rate of cardiovascular (CV) mortality is doubled in
patients with type 2 diabetes as compared to that of non
diabetic individuals [1] and definitively remains their first
cause of death [1]. The exact pathogenic mechanisms,
underlying such increased risk are poorly understood.
Adiponectin, a 244-amino acid protein secreted by adi-
pocytes has insulin-sensitizing, anti-inflammatory, and
endothelial protective effects [2,3] and exerts a protective
role in myocardial infarction (MI) [4,5] and coronary heart
disease (CHD) [6-8]. Thus, it is surprising that, high adi-
ponectin levels predict increased risk of heart failure (HF)
[9,10] as well as CV mortality in the general population
and in selected clinical settings [11-21]. A similar unex-
pected paradoxical association with the risk of CV mortal-
ity has been also described in patients with type 1 diabetes
[22] and in kidney transplant recipients [23]. Whether this
is the case also among patients with type 2 diabetes has
never been addressed.
Interestingly, it has been recently reported that in
humans there is a sex-specific effect of serum adiponectin
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gression of chronic kidney disease [25]; also data in mice
with genetically induced endothelial dysfunction in which
adiponectin exerts its beneficial effect on heart function
and remodeling in female but not male are compatible
with a sexual dimorphism [26]. While some studies have
not reported a sex-specific effect of adiponectin on CHD
[27] and cardiovascular events [28], no data are so far
available on CV mortality.
In order to investigate whether serum adiponectin plays
a role in CV mortality in type 2 diabetes in a sex-specific
manner, we analyzed data from over 2,000 diabetic pa-
tients of European origin from three independent estab-
lished cohorts from Italy and the US followed over time
for several years.
Material and methods
Study populations
GHS-prospective design
This study comprises 368 patients with type 2 diabetes
(ADA 2003 criteria) and coronary artery disease who
were consecutively recruited at the Endocrine Unit of
IRCCS “Casa Sollievo della Sofferenza” in San Giovanni
Rotondo (Gargano, Center East Coast of Italy) from 2001
to 2008, as recently described [29,30]. All patients had ei-
ther a stenosis >50% in at least one coronary major vessel
at coronary angiography or a previous MI. Follow-up in-
formation on outcomes was collected yearly from 2002
to 2011. The only exclusion criterion was the presence
of poor life expectancy for non diabetes-related diseases.
The end-point was here CV mortality. Confirmation of
the event was obtained from death certificates (i.e. ac-
cording to the international classification of diseases’
codes: 428.1- ninth edition - and I21.0-I21.9, I25.9,
I46.9-I50.9, I63.0, I63.9, I70.2- tenth edition).
Clinical data at baseline were obtained from a stan-
dardized interview and examination. Smoking habits and
history of hypertension, dyslipidemia and MI as well as
glucose-lowering treatment were also recorded at time
of examination. Data regarding medications were con-
firmed by review of medical records. Serum total and
high-molecular weight (HMW) adiponectin were mea-
sured in 359 (98%) participants.
The study was approved by the Institutional Ethic
Committee IRCCS “Casa Sollievo della Sofferenza”, San
Giovanni Rotondo.
Health Professional Follow-up Study (HPFS) and Nurses’
Health Study (NHS)
The HPFS is a prospective cohort study of 51,529 US
male health professionals who were 40 – 75 years old at
study inception in 1986 [31]. Between 1993 and 1999,
18,159 men provided blood samples. The NHS is a pro-
spective cohort study of 121,700 female registered nurses
who were 30 – 55 years old at study inception in 1976
when all of them completed a mailed questionnaire on
their medical history and lifestyle [32]. A total of 32,826
women provided blood samples between 1989 and 1990.
In both cohorts, information about health and disease
has been collected at baseline and biennially by self- ad-
ministered questionnaires since inception and renal
function was estimated by the simplified MDRD equa-
tion [33]. Study individuals in the present analysis from
both NHS and HPFS were all patients with type 2 dia-
betes who provided blood samples, during 1993 and
1994 for HPFS and during 1989 and 1990 for NHS, re-
spectively. We followed these subjects and documented
incident CV disease and related death after blood draw.
Diabetes cases were defined as self-reported diabetes at
baseline confirmed by a validated supplementary ques-
tionnaire. For study individuals recruited before the re-
lease of the American Diabetes Association criteria in
1997, the National Diabetes Data Group criteria were
used to define diabetes [34]. The validity of this method
has been confirmed [35]. The American Diabetes Associ-
ation diagnostic criteria were used for diabetes diagnosis
from 1998 onwards [36].
CV deaths were confirmed by review of medical re-
cords or autopsy reports with the permission of the next
of kin [37].
In the current prospective analysis of plasma total adi-
ponectin levels and CV mortality risk, where follow-up
began at the time of blood collection, participants with
established CV disease (defined as the occurrence of MI
or coronary artery bypass grafting or stroke) before the
diagnosis of diabetes were excluded from the present
analyses [38,39]. Eight hundred and thirty three diabetic
men (146 CV deaths during 14-year follow-up) and 902
diabetic women (144 CV deaths during 20-year follow-
up) were included.
The study was approved by the Human Research
Committee at the Brigham and Women’s Hospital, Boston,
MA, USA, and all participants provided written informed
consent.
Sample collection and measurement of circulating total
and HMW adiponectin levels
In the GHS-prospective designs blood samples were col-
lected between 8:00 and 9:00 AM after an overnight fast.
In the NHS and HPFS, blood samples were collected in
EDTA blood tubes in the men and heparin blood tubes in
the women, chilled, and sent back by prepaid overnight
courier. Once in the laboratory, the samples were centri-
fuged and aliquoted into cryotubes as plasma, buffy coat,
and red blood cells. Cryotubes were then stored in liquid
nitrogen freezers at −130°C or lower [40].
In the GHS-prospective design, serum total and
HMW adiponectin concentrations were measured by
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The intra-assay coefficients of variation were 5.4 and
4.9, and 5.0 and 4.8% for total adiponectin and HMW
adiponectin, respectively.
In the NHS and HPFS, plasma total adiponectin was
measured separately, in two different laboratories, by com-
petitive radioimmunoassay (Linco Research, St. Charles,
MO). A similar coefficient of variation ranging 3-4%, was
observed in both cohorts [42].
Statistical methods
Patients’ baseline characteristics were reported as mean±
standard deviation (SD), median (range) and percentages
for continuous and categorical variables, respectively.
In all prospective studies, the time variable was de-
fined as the time between the baseline examination and
date of the event (CV mortality), or, for subjects who did
not experience the event, the date of the last available
clinical follow-up. Incidence rates for CV mortality were
expressed as the number of events per total number of
person-years (py). Univariate and multivariate (taking
into account several covariates as described in Results)
Cox proportional hazards regression analyses were per-
formed to assess the association between adiponectin
values and the event occurrence. Risks were reported as
Hazard Ratios (HR) along with 95% CI per SD increase
in adiponectin levels and for tertiles of its distribution.
The same analyses were carried out in males and fe-
males from the GHS-prospective design, separately.
Linearity of association was tested comparing, in terms
of AIC (Akaike Information Criterion), a linear and a
quadratic model.
As a sensitivity analysis, we performed a competing
risks analysis, where the non CV death is the competitor
of CV death, using subdistribution hazard ratios estimated
through Fine and Gray proportional hazards regression [43].
Meta-analysis of pooled estimates was obtained using
the fixed effects meta-analysis model. Between-study het-
erogeneity was assessed using the Cochran Q test.
In the pooled analysis we had 80% power to detect an
HR of 1.25 for 1 SD adiponectin with a Type I Error
(alpha) of 0.05 both in men and in women.
A p-value <0.05 was considered as significant. All analyses
were performed using SAS Release 9.1.3 (SAS Institute, Cary,
NC, USA) and R software (package “cmprsk”).
Results
The GHS-prospective design
Baseline clinical features of study participants are sum-
marized in Table 1. During follow-up (5.4 ±2.5 years),
58 CV deaths occurred, corresponding to an overall an-
nual incidence rate of 3.0% (58 events/1,934 py). Median
serum total adiponectin was 4.4 (range: 0.97-21.8) μg/ml.
Each SD increment of serum adiponectin was associated
with a 30% increase in the risk of CV mortality (HR=
1.30, 95% CI: 1.09-1.56, p=0.005). The linearity of this as-
sociation was confirmed by comparing AICs (linear: 632.6
vs. quadratic: 633.5).
This association was independent of baseline clinical
features including age, sex, smoking habits, BMI, HbA1c,
anti-diabetic therapy, hypertension, total cholesterol, HDL
cholesterol, triglycerides and hsCRP (adiponectin SD
HR=1.44, 95% CI: 1.14-1.82; p=0.002). Duration of
diabetes was not included in this model because collin-
ear with age at recruitment.
In contrast, no association was observed with non CV
death (23 events; HR = 1.07, 95% CI: 0.73-1.55; p= 0.74);
this makes very likely that the association we observed
with all-cause mortality (81 events; HR =1.24, 95% CI:
1.05-1.46; p =0.01) is mainly driven by that with CV
mortality.
Finally, competing risks analysis, in which non CV
death was used as competing risk, provided further sup-
port to the association between serum adiponectin and
CV mortality (HR =1.24, 95% CI: 1.08-1.43, p =0.003).
According to our predefined aim, data were then ana-
lyzed in men and women, separately. Median (range) total
adiponectin were 4.2 (0.97-21.8) and 5.0 (0.67-19.2), in
men and women, respectively. The association with CV
mortality was clearly evident and statistically significant
among men (adiponectin SD HR=1.41, 95% CI: 1.16-
1.70), but not women (adiponectin SD HR=1.02, 95% CI:
0.63-1.62) (Table 2), thus suggesting differences across sex
(p for HR heterogeneity 0.09). The linearity of the associ-
ation was confirmed by comparing AICs (linear: 417.0 vs.
quadratic: 417.8). This association did not significantly
change in the adjusted model (Table 2).
When men were stratified according to tertiles of adi-
ponectin levels a trend toward an increased risk of CV
mortality from tertile 1 (i.e. the lowest values) to tertile 3
(i.e. the highest values) was observed (adjusted p for
trend = 0.026) (Figure 1).
Very similar associations both in the whole sample as
well as in men and women analyzed separately were
obtained for HMW adiponectin (see Additional file 1:
Table S1).
The HPFS
The baseline clinical features of study participants, in-
cluding by study design, only male patients, are summa-
rized in Table 1. During an average 14 years (1994–
2008) of follow-up since blood samples were obtained,
146 CV deaths occurred in 10,024 py, corresponding to
an overall annual incidence rate of 2.8%. Median plasma
total adiponectin was 14.07 (range: 1.41-63.78) μg/ml.
Mirroring the results obtained among men from the
GHS-prospective design, plasma adiponectin levels were
associated with CV mortality (adiponectin SD HR =1.26,
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was confirmed by comparing AICs (linear: 1583 vs. quad-
ratic: 1590). This association did not significantly change in
the adjusted model (Table 2).
Further adjustments for alcohol consumption and
eGFR values (which were not available in the GHS) did
not change the observed association (adiponectin SD
HR =1.46, 95% CI: 1.24-1.72).
Also in this case tertiles stratification according to adi-
ponectin levels, revealed a trend toward an increased CV
mortality rate (adjusted p for trend <0.0001) (Figure 1).
The NHS
Baseline clinical features of study participants, including
by study design, only female patients, are summarized in
Table 1. During an average 20-year follow-up (1990–
2010), 144 CV deaths occurred 15,074 py, corresponding
to an overall annual incidence rate of 1.9%. Median
plasma adiponectin was 5.88 (range: 0.80-42.07) μg/ml.
Mirroring the results obtained among women from the
GHS-prospective design, total plasma adiponectin was
not associated with CV mortality (HR = 0.91, 95% CI:
0.75-1.09) (Table 2). This association did not significantly
change in the adjusted model (Table 2). Similar results were
obtained after further adjustment for alcohol consumption
and renal function (HR= 1.05, 95% CI: 0.85-1.31).
Pooled analysis
In a pooled analysis, the association between circulating
adiponectin and CV mortality was strongly evident among
men (adjusted HR=1.47, 95% CI 1.27-1.70, p=2×10
−7),
but not among women (adjusted HR=1.07, 95% CI
0.86-1.33, p=0.53) Table 2. The difference between HRs
Table 1 Baseline clinical characteristics of participants from GHS-prospective design, NHS and HPFS cohorts
GHS-prospective design HPFS NHS
Men (n=242) Women (n= 117) Men (n= 833) Women (n=902)
Age (years) 63.6± 8.3 66.1±7.5 63.6±8.6 59.1±7.2
Current Smokers (%) 55 (22.7) 9 (7.7) 56 (6.7) 123 (13.6)
Diabetes duration (years) 12.9± 8.8 15.7±9.8 7.8± 9.6 11.0±9.3
BMI (kg/m
2) 29.4± 4.3 31.8±5.4 27.8±4.6 29.7±6.3
HbA1C % (mmol/mol) 8.6±1.9 (70±20.8) 8.7±1.8 (72±19.7) 7.3± 1.5 (56±16.4) 7.1± 1.8 (54± 19.7)
Total cholesterol (mg/dl) 175.4±46.0 176.7± 45.3 209.6± 40.4 229.6±45.4
HDL-cholesterol (mg/dL) 42.2± 14.2 46.4±15.0 40.2±11.1 51.7±15.9
Triglycerides (mg/dL) 158.5±98.8 140.3± 74.3 191.0± 101.7 208.9±152.4
hsCRP (mg/L) 6.7±14.3 4.9±8.3 3.2+ 5.4 7.9± 8.8
Anti-diabetic therapy (%) 126 (52.0) 68 (58.1) 603 (72.4) 493 (54.7)
Hypertension (%) 198 (81.8) 107 (91.5) 393 (47.2) 599 (66.4)
Continuous variables were reported as mean± SD whereas categorical variables as total frequency and percentages.
GHS: Gargano Heart Study; HPFS: Health Professional Follow-up Study: NHS, Nurses’ Health Study.
BMI: body mass index; HbA1c: glycated haemoglobin A1c, hsCRP: high sensitivity C-reactive protein.
Table 2 Risk of cardiovascular mortality by 1 SD of circulating adiponectin levels
Model 1 Model 2
Study samples Number of participants/events HR (95% CI) p value HR (95% CI) p value
Men
GHS 242/42 1.41 (1.16-1.70) 5×10
−4 1.54 (1.19-2.01) 1×10
−3
HPFS 833/146 1.26 (1.10-1.45) 1×10
−3 1.44 (1.21-1.72) 1×10
−4
POOLED§ 1075/188 1.31 (1.17-1.47) 2×10
−6 1.47 (1.27-1.70)* 2×10
−7
Women
GHS 117/16 1.02 (0.63-1.62) 0.82 0.98 (0.48-2.01) 0.96
NHS 902/144 0.91 (0.75-1.09) 0.31 1.08 (0.86-1.35) 0.49
POOLED
§ 1019/160 0.92 (0.78-1.10) 0.37 1.07 (0.86-1.33) 0.53
GHS, Gargano Heart Study; HPFS, Health Professional Follow-up Study; NHS, Nurses’ Health Study.
Model 1: unadjusted.
Model 2: adjusted for age, sex, smoking habit, BMI, HbA1c, anti-diabetic therapy, hypertension, total cholesterol, HDL cholesterol, triglycerides and hsCRP.
§pooled analyses were adjusted for “study sample”.
*p= 0.018 vs. model 2, pooled HR in women.
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(p for heterogeneity=0.018).
Discussion
In this study we investigated in three different cohorts
the association of circulating adiponectin on CV mor-
tality in men and women with type 2 diabetes. To the
best of our knowledge, this is the first report showing
that i) adiponectin is positively related to CV mortality
in type 2 diabetes and ii) a sexual dimorphism influ-
ences such paradoxical association, which is observable
only in men.
Despite the direct association between serum adipo-
nectin and CV mortality is difficult to reconcile with the
well-recognized role of adiponectin as an anti inflamma-
tory, anti-atherogenic and insulin sensitizer factor [2,3]
and with the previously reported association with re-
duced risk of CHD [6,7,27], the same counter intuitive
finding has been recently described in individuals from
the general population and several selected clinical setting
[11-17,19-23]. In addition, high adiponectin levels have
been reported to predict all-cause mortality in the general
population and in patients with CV disease [18-21], as
well as in elderly people with type 2 diabetes [44].
Taken together our present and all previous studies
strongly point to a paradoxical association of serum adi-
ponectin on mortality rate.
The biology underlying such unexpected association is
unknown and cannot be unraveled by observational
studies. One can here only speculate that, in our study,
increased adiponectin may be interpreted as a marker of
a tentative, though not sufficient, homeostatic mechanism
in individuals who are at high CV risk [45]. Conversely, it
is also possible that in some individuals, serum adiponec-
tin is increased because of adiponectin resistance, which,
in turn, does have the potential of playing a direct patho-
genic role in increasing risk of CV mortality [3,46,47]. It
is also possible that increased adiponectin levels is a
consequence of increased N-terminal pro brain natri-
uretic peptide (NT-proBNP) [18], an established marker
of CV disease.
The second important finding of our study is the sex-
specific association between circulating adiponectin and
CV mortality with the deleterious role of high adiponectin
levels being observable only among men. Controversial
findings have been so far reported as far as a sexually di-
morphic association of adiponectin with metabolic and
atherosclerosis-related clinical events is concerned. In fact,
while no sex-specific association has been described on
CHD in the general population [27] and on CV events in
a very small sample of patients with type 2 diabetes [28],
high adiponectin levels do predict progressive kidney dys-
function among men, but not women, in individuals with
chronic kidney disease [25].
Whether the sex specific associations of adiponectin
on metabolic and atherosclerosis-related events we and
others [24,25] observed is due to the interaction between
circulating adiponectin and either sex-linked genes and/
or sexual hormone effects is not known and deserves
further investigations. Sex-specific associations have
been reported also for other CV risk factors, including
those between elevated plasma levels of sTNF-receptors
and coronary heart disease [48], between uric acid and
atrial fibrillation [49] and between prolactin and cardiac
remodeling [50]. A better understanding of the different
role of adiponectin on CV disease across sexes, might be
gained by verifying whether adiponectin changes, as ob-
tained by interventional studies, are differently related to
CV outcomes in males and females.
We acknowledge that the statistical level of sex-specific
association indicate the need of caution in interpreting
our results. Nonetheless, while waiting for further stud-
ies in additional samples, present and previous findings
[24,25], definitively suggest the need of taking into ac-
count possible sex-specific associations when addressing
the role of CV risk factors; in addition, they point to the
Figure 1 Hazard ratios (95% CI) of CV mortality in men from the GHS-prospective design and HPFS, according to baseline tertile of
circulating adiponectin levels (T1-T3, range in parentheses). Hazard ratios were estimated by Cox regression after adjusting for age, sex,
smoking habits, BMI, HbA1c, anti-diabetic therapy, hypertension, total cholesterol, HDL cholesterol, triglycerides and hsCRP.
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ravel the different biology underlying CV risk in men
and women.
Our study has some strength as follows. We utilized
well-established prospectively analyzed cohorts with a
completeness of information, including standardized
clinical evaluations and hard end-points validated by
medical records or death certificates. In addition, in the
GHS-prospective design, very similar data were ob-
tained with HMW-adiponectin, the biological active
form of circulating adiponectin, thus reinforcing data
obtained by measuring total adiponectin levels. Most
importantly, the sex-specific association of adiponectin
on CV death, which has been validated in independent
samples, is entirely novel and plays the important func-
tion of reinforcing the belief that a different biology un-
derlies CV risk in men and women [51]. Finally, since
our results were very similar in individuals from both
Italy and the US, it is very likely that they can be general-
ized to all diabetic patients of European ancestry, no mat-
ter where they live and the environment they are exposed
to. In this context, it is of note that several clinical fea-
tures, including HbA1c, the proportion of hypertension,
and - as far as males from HPFS are concerned - a rela-
tively low proportion of smokers -, were quite heteroge-
neous across study populations.
A major limitation of our investigation is intrinsic to
its very nature. As an observational study, it cannot ad-
dresses mechanistic explanations of the association we
observed, with only hypothesis being offered.
In addition, it remains unknown whether the para-
doxical association between serum adiponectin and CV
mortality we observed in men of European ancestry is a
general phenomenon also observable in individuals of dif-
ferent ancestries. Also, given that adiponectin measure-
ment was carried out in different specimens (i.e. serum or
plasma) by three different laboratories using different as-
says, a direct comparison of absolute values across the dif-
ferent study samples cannot be done. Finally, the role of
potential bias affecting adiponectin levels, including poly-
pharmacy, diabetic kidney disease and other residual or
unmeasured confounding factors not taken into account
in our study cannot be excluded, thus inviting for caution
in interpreting our results.
In conclusion, to the best of our knowledge this is the
first study reporting that, quite unexpectedly given its
beneficial role in atherosclerotic processes [2,3], high cir-
culating adiponectin predicts increased CV mortality in
patients with type 2 diabetes. It is of note that such associ-
ation was only observed in diabetic men, whereas no asso-
ciation at all was detected in diabetic women. Further
studies aimed at unraveling the mechanisms through
which adiponectin influences CV mortality and how this
occurs in a sex-specific manner are certainly required.
The composite, not straightforward, scenario drawn by
our findings points to the general need of characterizing
in deep details the role of novel and promising markers of
CV disease before to upgrade them at the level of usable
tools in the clinical set.
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